A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.

Michael CecchiniJeremy S KortmanskyCan CuiWei WeiJaykumar Ranchobdhai ThumarNataliya V UbohaNavid HafezJill LacyNeal A FischbachKert D SabbathChristina M GomezJonathan Reed SpornStacey SteinHoward S Hochster

Published in: Cancer (2020)

For metastatic colorectal cancer, the treatment combination of TAS-102 and oxaliplatin was found to be well-tolerated and revealed no unexpected side effects. Twelve of 41 patients had reductions in the size of their tumor, and the study treatment delayed the time to tumor growth as opposed to what would be expected.

Keyphrases

metastatic colorectal cancer
ejection fraction
newly diagnosed
single cell
patient reported